SCHEMBL18477405

SCHEMBL18477405

CNC(=O)CC(CC(=O)NC)NC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRAT P43155 1/20 0.42
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
PTGS2 P35354 1/20 0.35
THPO P40225 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MCL1 Q07820 1/20 0.34
LMNA P02545 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PLA2G2C Q5R387 2/20 0.33
ATM Q13315 1/20 0.33
ADAM17 P78536 2/20 0.31
MMP1 P03956 2/20 0.30
MMP2 P08253 2/20 0.30
MMP3 P08254 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21335957 0.82 PLA2G2C (0.47) CRATLMNAPLA2G2C
SCHEMBL12785388 0.79 MTNR1A (0.38) CRATKDM4EMAPTTHRBALOX15
Hydrochloric Acid SCHEMBL6045018 0.77 MTNR1A (0.37) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL12216792 0.77 MCL1 (0.39) MAPTMCL1LMNAALDH1A1ATM
SCHEMBL21398592 0.76 BMP1 (0.41) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL20886556 0.76 MAPT (0.55) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL10936490 0.75 CRAT (0.45) CRATKDM4EMAPTTHRBALOX15
SCHEMBL15514478 0.71 LMNA (0.36) KDM4EMAPTSMN1; SMN2MCL1LMNA
SCHEMBL11311284 0.71 MGAM (0.44) CRATKDM4EMAPTTHRBALOX15
SCHEMBL4903843 0.71 ATM (0.34) MAPTMCL1LMNAATMPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210340210-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER NEKTAR THERAPEUTICS (US) 2021-11-04 US disclosed
US-11141465-B2 Method of making a water-soluble polymer-factor VIII moiety conjugate NEKTAR THERAPEUTICS (US) 2021-10-12 US disclosed
US-11091525-B2 Method of refolding an interleukin-2 (IL-2) protein NEKTAR THERAPEUTICS (US) 2021-08-17 US disclosed
US-10960079-B2 Conjugates of an IL-2 moiety and a polymer NEKTAR THERAPEUTICS (US) 2021-03-30 US disclosed
US-20210023230-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER NEKTAR THERAPEUTICS (US) 2021-01-28 US disclosed
US-20210023186-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2021-01-28 US disclosed
US-10232042-B2 Conjugates of an anti-TNF-alpha antibody NEKTAR THERAPEUTICS (US) 2019-03-19 US disclosed
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-20180207286-A1 CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2018-07-26 US disclosed
US-9999657-B2 Polymer-factor VIII moiety conjugates NEKTAR THERAPEUTICS (US) 2018-06-19 US disclosed
US-20180085468-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2018-03-29 US disclosed
US-9763995-B2 Polymer conjugates of protegrin peptides NEKTAR THERAPEUTICS (US) 2017-09-19 US disclosed
US-20170196975-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY NEKTAR THERAPEUTICS 2017-07-13 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-9636412-B2 Conjugates of an anti-TNF-alpha antibody NEKTAR THERAPEUTICS (US) 2017-05-02 US disclosed
US-20170035896-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS 2017-02-09 US disclosed
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340210-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER IL2, IL2RA, ILF2 CRAT 4378/4885KDM4E 4220/4885MAPT 1364/4885
US-10960079-B2 Conjugates of an IL-2 moiety and a polymer IL2, IL2RA, ILF2 CRAT 4378/4885KDM4E 4220/4885MAPT 1364/4885
US-11091525-B2 Method of refolding an interleukin-2 (IL-2) protein IL2, IL2RA, ILF2 CRAT 4261/4885KDM4E 4646/4885MAPT 668/4885
US-20170035896-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 CRAT 4102/4885KDM4E 3324/4885MAPT 2188/4885
US-20170196975-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY TNF, TNFRSF1A, TNFRSF9 CRAT 3796/4885KDM4E 4660/4885MAPT 662/4885
US-20180085468-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER IL2, IL2RA, ILF2 CRAT 4378/4885KDM4E 4220/4885MAPT 1364/4885
US-20180207286-A1 CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER BCHE, ACHE, DNPEP CRAT 90/4885KDM4E 2124/4885MAPT 403/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP CRAT 4001/4885KDM4E 4758/4885MAPT 405/4885
US-20210023230-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER IL2, IL2RA, ILF2 CRAT 4378/4885KDM4E 4220/4885MAPT 1364/4885
US-20210023186-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 CRAT 4102/4885KDM4E 3324/4885MAPT 2188/4885
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER IL15, IL15RA, IL2 CRAT 3873/4885KDM4E 4433/4885MAPT 1315/4885
US-10232042-B2 Conjugates of an anti-TNF-alpha antibody TNF, TNFRSF1A, TNFRSF9 CRAT 3796/4885KDM4E 4660/4885MAPT 662/4885
US-11141465-B2 Method of making a water-soluble polymer-factor VIII moiety conjugate F8, F13B, F13A1 CRAT 2828/4885KDM4E 3058/4885MAPT 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.